CD1A抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using CD1A mouse mAb against K562 (1), RAJI (2), and MOLT4 (3) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of RAJI cells using CD1A mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues (left) and colon cancer tissues (right) using CD1A mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain tissues (left) and submaxillary tumor tissues (right) using CD1A mouse mAb with DAB staining.    

  
  

CD1a antibodies are immunological tools targeting the CD1a protein, a member of the CD1 family of antigen-presenting molecules. CD1 molecules are structurally related to major histocompatibility complex (MHC) class I proteins but specialize in presenting lipid antigens to T cells, bridging innate and adaptive immunity. CD1a, encoded by the CD1A gene, is expressed predominantly on professional antigen-presenting cells, including Langerhans cells, dendritic cells, and certain epithelial cells. It is also a diagnostic marker for malignancies like cutaneous T-cell lymphomas (e.g., mycosis fungoides) and Langerhans cell histiocytosis.

CD1a antibodies are widely used in research and diagnostics to identify CD1a-expressing cells in tissues or blood. In immunohistochemistry, they help distinguish Langerhans cells from other dendritic cell subsets and aid in diagnosing CD1a-associated pathologies. Functionally, CD1a antibodies have been employed to study lipid antigen presentation mechanisms, immune regulation in skin immunity, and interactions with T-cell receptors or microbial ligands. Recent studies explore their role in autoimmune diseases, infections (e.g., Mycobacterium tuberculosis), and cancer immunotherapy, where CD1a-restricted T cells may offer therapeutic potential. Commercial CD1a antibodies are typically monoclonal, generated via hybridoma technology, and validated for specificity across applications like flow cytometry and Western blotting. Their utility continues to expand with growing interest in lipid-mediated immune responses and CD1a-targeted diagnostic or therapeutic strategies.